On December 11, 2025, a new clinical study titled “CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material” was highlighted, marking a significant milestone for medical device innovation in embolic protection during aortic valve interventions. The trial, supported by EmStop Inc. and Bright Research Partners, aims to advance patient safety by rigorously testing two devices designed for embolic material reduction during high-risk heart procedures.
What changed?
The CAPTURE-2 trial has been listed as “Not yet recruiting,” signaling that enrollment is forthcoming. This trial focuses on evaluating advanced medical devices for cardiovascular health. The study targets the growing population of patients with aortic valve stenosis and related conditions who may benefit from safer procedural options.
Study design and objective
The CAPTURE-2 trial will compare two embolic protection systems designed to reduce periprocedural risk associated with aortic valve replacement. The primary objective is to collect clinical insights and determine which system better mitigates the risk of embolic debris entering critical blood vessels.
Aortic valve stenosis, characterized by the narrowing of the aortic valve, poses high risks during catheter-based interventions. Embolic protection devices aim to reduce the chance of debris dislodgement—a significant safety concern during such procedures.
Devices under evaluation
This study will evaluate two devices:
- EmStop Embolic Protection System: Manufactured by EmStop Inc., the exact design features and mechanism of this system are under clinical assessment.
- Boston Scientific Sentinel: A widely recognized embolic protection device already present in the market and known for its two-filter system. This acts as a comparator device for evaluating the performance of EmStop’s new system.
Each device will be reviewed for efficacy, safety, and clinical applicability, aligning with international medical device regulatory standards.
Next steps and implications
The results of the CAPTURE-2 trial could directly influence clinical practice guidelines and inform policymakers. If successful, new safety benchmarks may require physicians to consider embolic protection systems as a standard feature during valve replacement procedures.
Industry stakeholders, including clinical, regulatory, and quality teams, should remain updated on the progress of this trial. This investigation could provide actionable insights for future registry-based studies or device approvals under stricter regulations.
FAQs
- What is the objective of the CAPTURE-2 trial? The goal is to evaluate the clinical performance and safety of two embolic protection systems during procedures for aortic valve stenosis.
- Who sponsors this trial? The study is sponsored by medical device company EmStop Inc. and Bright Research Partners.
- When will the trial start recruiting? As of now, recruitment has not begun, but updates will follow in due course.
- What conditions are targeted by this trial? Patients with aortic valve stenosis, aortic stenosis, and aortic valve disease represent the key population for this study.
Conclusion
The CAPTURE-2 trial could offer new treatment options for patients undergoing aortic valve interventions. Industry professionals should monitor updates from ClinicalTrials.gov and the manufacturers involved for actionable findings.
Disclaimer
This content is for informational purposes only and is not intended as legal or regulatory advice. Always consult qualified professionals for compliance guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07276711?term=medical+device